Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Income Statement
Earnings Waterfall
Cyclacel Pharmaceuticals Inc
Revenue
|
420k
USD
|
Operating Expenses
|
-25.9m
USD
|
Operating Income
|
-25.5m
USD
|
Other Expenses
|
2.7m
USD
|
Net Income
|
-22.8m
USD
|
Income Statement
Cyclacel Pharmaceuticals Inc
Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
1
N/A
|
1
+18%
|
1
+8%
|
2
+31%
|
2
-4%
|
2
+8%
|
2
-3%
|
2
-1%
|
2
+9%
|
2
-19%
|
2
-5%
|
1
-34%
|
1
-15%
|
1
-15%
|
0
-31%
|
0
-43%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+4%
|
0
+9%
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(19)
|
(21)
|
(22)
|
(22)
|
(24)
|
(24)
|
(22)
|
(20)
|
(18)
|
(16)
|
(16)
|
(16)
|
(15)
|
(14)
|
(12)
|
(11)
|
(9)
|
(9)
|
(9)
|
(9)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(11)
|
(13)
|
(16)
|
(20)
|
(23)
|
(25)
|
(25)
|
(25)
|
(28)
|
(28)
|
(29)
|
(29)
|
(26)
|
|
Selling, General & Administrative |
(8)
|
(7)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
|
Research & Development |
(11)
|
(14)
|
(16)
|
(16)
|
(18)
|
(18)
|
(16)
|
(14)
|
(12)
|
(11)
|
(11)
|
(10)
|
(9)
|
(8)
|
(7)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(9)
|
(12)
|
(15)
|
(18)
|
(18)
|
(18)
|
(20)
|
(21)
|
(22)
|
(22)
|
(19)
|
|
Operating Income |
(18)
N/A
|
(19)
-8%
|
(21)
-7%
|
(21)
+1%
|
(22)
-9%
|
(22)
+0%
|
(20)
+9%
|
(18)
+11%
|
(16)
+11%
|
(15)
+10%
|
(15)
-1%
|
(15)
-1%
|
(14)
+5%
|
(13)
+7%
|
(12)
+10%
|
(10)
+12%
|
(9)
+9%
|
(9)
+6%
|
(9)
+0%
|
(9)
-4%
|
(10)
-3%
|
(10)
-1%
|
(9)
+1%
|
(9)
+1%
|
(10)
-3%
|
(10)
-2%
|
(10)
-1%
|
(10)
-2%
|
(11)
-4%
|
(13)
-18%
|
(16)
-29%
|
(20)
-21%
|
(23)
-17%
|
(25)
-10%
|
(25)
+1%
|
(25)
-2%
|
(28)
-9%
|
(28)
-3%
|
(29)
0%
|
(29)
-1%
|
(25)
+12%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
1
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
1
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
(0)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
6
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(12)
N/A
|
(14)
-18%
|
(21)
-49%
|
(21)
+0%
|
(23)
-9%
|
(23)
-1%
|
(21)
+8%
|
(19)
+12%
|
(16)
+11%
|
(14)
+13%
|
(14)
+1%
|
(14)
-1%
|
(14)
+4%
|
(12)
+12%
|
(11)
+9%
|
(10)
+12%
|
(8)
+12%
|
(8)
+4%
|
(8)
+1%
|
(8)
-4%
|
(9)
-4%
|
(9)
-7%
|
(9)
+3%
|
(9)
+2%
|
(9)
-4%
|
(9)
+7%
|
(9)
-4%
|
(9)
-4%
|
(10)
-5%
|
(12)
-27%
|
(16)
-29%
|
(19)
-22%
|
(23)
-17%
|
(24)
-5%
|
(23)
+2%
|
(23)
-1%
|
(26)
-11%
|
(28)
-7%
|
(28)
-2%
|
(29)
-2%
|
(26)
+11%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
2
|
2
|
3
|
3
|
3
|
3
|
3
|
3
|
2
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
4
|
3
|
|
Income from Continuing Operations |
(10)
|
(12)
|
(18)
|
(18)
|
(19)
|
(19)
|
(18)
|
(16)
|
(14)
|
(12)
|
(12)
|
(12)
|
(12)
|
(10)
|
(10)
|
(8)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(8)
|
(7)
|
(8)
|
(8)
|
(8)
|
(11)
|
(14)
|
(16)
|
(19)
|
(20)
|
(19)
|
(19)
|
(21)
|
(23)
|
(24)
|
(25)
|
(23)
|
|
Net Income (Common) |
(19)
N/A
|
(13)
+34%
|
(19)
-49%
|
(18)
+4%
|
(20)
-7%
|
(20)
0%
|
(18)
+7%
|
(16)
+12%
|
(15)
+9%
|
(13)
+13%
|
(12)
+3%
|
(13)
-2%
|
(12)
+4%
|
(11)
+12%
|
(10)
+7%
|
(16)
-61%
|
(15)
+5%
|
(15)
+1%
|
(14)
+2%
|
(8)
+48%
|
(7)
+0%
|
(8)
-7%
|
(8)
+1%
|
(8)
+2%
|
(8)
-4%
|
(7)
+8%
|
(8)
-5%
|
(8)
-5%
|
(12)
-52%
|
(15)
-18%
|
(18)
-20%
|
(20)
-15%
|
(19)
+6%
|
(20)
-3%
|
(19)
+3%
|
(19)
-1%
|
(21)
-11%
|
(23)
-8%
|
(24)
-4%
|
(25)
-4%
|
(23)
+9%
|
|
EPS (Diluted) |
-243.5
N/A
|
-160.37
+34%
|
-212.44
-32%
|
-203.88
+4%
|
-217.66
-7%
|
-178.45
+18%
|
-201.88
-13%
|
-114.07
+43%
|
-103.85
+9%
|
-84.53
+19%
|
-4.09
+95%
|
-73.76
-1 703%
|
-3.5
+95%
|
-50.09
-1 331%
|
-44.27
+12%
|
-31.95
+28%
|
-39.07
-22%
|
-24.41
+38%
|
-23.85
+2%
|
-12.53
+47%
|
-12.48
+0%
|
-11.73
+6%
|
-9.19
+22%
|
-9
+2%
|
-9.79
-9%
|
-8.62
+12%
|
-2.02
+77%
|
-1.67
+17%
|
-3.42
-105%
|
-2.06
+40%
|
-1.91
+7%
|
-2.17
-14%
|
-2.14
+1%
|
-1.97
+8%
|
-1.89
+4%
|
-1.56
+17%
|
-1.9
-22%
|
-1.84
+3%
|
-1.92
-4%
|
-29.47
-1 435%
|
-26.75
+9%
|